News
Sarepta reports second patient death after treatment with Duchenne gene therapy
Cambridge-based Sarepta Therapeutics said it was halting shipments of its Duchenne muscular dystrophy gene therapy for patients who can no longer walk, following the death of a second person who received the treatment.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided a safety ...
Sarepta suspends Elevidys use in non-ambulatory Duchenne patients after two liver failure deaths, triggering FDA review and ...
Sarepta's stock drops on ELEVIDYS safety concerns, yet potential remains for ambulatory patients. Click here to read an ...
Stocks were rising Monday after The Wall Street Journal reported Tehran was looking to resume talks with the White House over ...
Another gene therapy death of a Duchenne patient has some parents and doctors criticizing the FDA's actions, even as other ...
Despite setbacks, Sarepta’s gene therapy pipeline and market leadership in DMD present a high-risk, high-reward setup. Read ...
The death of a second patient taking Sarepta Therapeutics' controversial gene therapy for Duchenne muscular dystrophy caused shares of Sarepta to plunge, and raised questions about the viability of ...
Eli Lilly is buying Verve Therapeutics, developer of gene-editing treatments for cardiovascular disease, for $1 billion plus ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback